Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Accumulated Expenses (2020 - 2025)

Gain Therapeutics has reported Accumulated Expenses over the past 6 years, most recently at $1.0 million for Q3 2025.

  • Quarterly results put Accumulated Expenses at $1.0 million for Q3 2025, down 31.82% from a year ago — trailing twelve months through Sep 2025 was $1.0 million (down 31.82% YoY), and the annual figure for FY2024 was $1.4 million, up 89.6%.
  • Accumulated Expenses for Q3 2025 was $1.0 million at Gain Therapeutics, up from $547270.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for GANX hit a ceiling of $2.1 million in Q3 2022 and a floor of $325079.0 in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $1.1 million (2024), compared with a mean of $1.1 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 229.27% in 2022 and later crashed 59.57% in 2025.
  • Gain Therapeutics' Accumulated Expenses stood at $681770.0 in 2021, then soared by 58.72% to $1.1 million in 2022, then plummeted by 32.86% to $726474.0 in 2023, then soared by 89.6% to $1.4 million in 2024, then decreased by 23.96% to $1.0 million in 2025.
  • The last three reported values for Accumulated Expenses were $1.0 million (Q3 2025), $547270.0 (Q2 2025), and $1.2 million (Q1 2025) per Business Quant data.